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Abstract
Rationale Advances in understanding the underlying mecha-
nisms of conditions such as fragile X syndrome (FXS) and
autism spectrum disorders have revealed heterogeneous pop-
ulations. Recent trials of novel FXS therapies have highlight-
ed several challenges including subpopulations with possibly
differential therapeutic responses, the lack of specific outcome
measures capturing the full range of improvements of patients
with FXS, and a lack of biomarkers that can track whether a
specific mechanism is responsive to a new drug and whether
the response correlates with clinical improvement.
Objectives We review the phenotypic heterogeneity of FXS
and the implications for clinical research in FXS and other
neurodevelopmental disorders.
Results Residual levels of fragile X mental retardation protein
(FMRP) expression explain in part the heterogeneity in the
FXS phenotype; studies indicate a correlation with both cog-
nitive and behavioral deficits. However, this does not fully
explain the extent of phenotypic variance observed or the
variability of drug response. Post hoc analyses of studies
involving the selective mGluR5 antagonist mavoglurant and
the GABAB agonist arbaclofen have uncovered significant
therapeutic responses following patient stratification
according to FMR1 promoter methylation patterns or baseline
severity of social withdrawal, respectively. Future studies
designed to quantify disease modificationwill need to develop
new strategies to track changes effectively over time and in
multiple symptom domains.
Conclusion Appropriate selection of patients and outcome
measures is central to optimizing future clinical investigations
of these complex disorders.
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Introduction
Based on advances in the understanding of the neurobiology
of fragile X syndrome (FXS), targeted therapeutic agents
designed to correct the underlying mechanisms of neural
dysfunction have been assessed in patients. Investigating these
new therapies for FXS in clinical trials has led to an increased
understanding of the challenges involved in evaluating treat-
ment efficacy in this complex condition. In particular, these
early trials have highlighted several challenges: (a) heteroge-
neity, with the existence of subpopulations based on differing
therapeutic response; (b) the lack of reliable biomarkers; and
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(c) the issue of specific and sensitive outcome measures,
particularly in the context of future disease modification trials.
FXS is among the most common known inherited causes of
intellectual disability and autism, typically caused by expan-
sion of a cytosine–guanine–guanine (CGG) triplet repeat in
the 5′ untranslated region of the fragile mental retardation 1
(FMR1 ) gene. The presence of >200 CGG repeats (full mu-
tation), combined with extensive methylation of the FMR1
promoter, containing the repeat sequence and upstream CpG
islands, leads to transcriptional silencing of FMR1 and a
complete or partial absence of fragile mental retardation pro-
tein (FMRP) (Bell et al. 1991; Sutcliffe et al. 1992). FMRP is a
dendritic RNA binding protein that modulates local transla-
tion of mRNA at the synapse and postsynaptic density.
Dendritic translation, in turn, influences the morphology and
functionality of the synapse (synaptic plasticity). Loss of
FMRP leads to dysregulation of translation and abnormal
neuronal signaling in specific pathways, culminating in the
morphological defects and aberrant synaptic plasticity ob-
served in Fmr1-knockout animal models and post mortem
brain tissue from individuals with FXS.
In addition to cognitive deficits, individuals with FXS typ-
ically present behavioral problems which include a range of
anxiety symptoms, attention deficits, hyperarousal, irritability,
and autism or autistic-like symptoms including social deficits
(Garber et al. 2008). Despite a common genetic etiology, there
is a wide-ranging variability in clinical presentation of FXS.
Many of these symptoms are shared with autism spectrum
disorders (ASD), and approximately 2–6 % of all cases of
autism in males are caused by FXS (Hagerman et al. 2010),
dependent on the intelligence quotient (IQ) level of the autism
cohort. The prevalence of autism among individuals with FXS
is approximately 30 % when using the Autism Diagnostic
Observation Schedule/Autism Diagnostic Interview—
Revised (Hall et al. 2008; Harris et al. 2008; Kaufmann
et al. 2004; Rogers et al. 2001).
The mechanistic link underlying the high prevalence of
autism in FXS may be mediated via FMRP and its role in
regulating translation of a large number of proteins associated
with autism: mGluR5, N-methyl-D-aspartate receptor subunits,
mammalian target of rapamycin (mTOR), tuberous sclerosis
complex 2, fragile-X-related protein 2, and neuroligin-3
(Ascano et al. 2012; Darnell et al. 2011; Iossifov et al. 2012).
Many of these genes are associated with synaptic plasticity and
function. The molecular pathways underlying the overlap be-
tween FXS and autism are complicated and poorly understood.
A comprehensive review of the overlap between autism and
FXS is beyond the scope of this paper, and several excellent
reviews have been published on the topic.
In this review, we will discuss the clinical and molecular
heterogeneity of FXS and the implications for clinical re-
search. We will also highlight how future trials will need to
carefully consider selection of the most appropriate patients
and outcome measures, particularly in the context of evaluat-
ing disease modification. We will also consider the wider
implications for other neurodevelopmental disorders, and
whether what is learned from translational research in FXS
can be extrapolated to other etiologies of ASD.
Fragile X syndrome—a clinically heterogeneous patient
population
The significant heterogeneity in behavioral and cognitive deficits
observed among individuals with FXS is explained in part by
variations in residual levels of FMRP. The latter is determined by
mosaicism of the CGG expansion size, methylation levels, andX
chromosome inactivation. In females, inactivation of one of the
twoX chromosomes is random from one cell to the next, leading
to a differential pattern of FMRP expression within tissues. As a
result, the ratio of active normal and full mutation X chromo-
somes (X-activation ratio) significantly influences the extent of
an individual’s symptoms; all females with FXS are mosaic by
definition. Similarly, in males, variations in the pattern of meth-
ylation or size of CGG expansion can result in mosaicism, in
which transcriptional silencing of FMR1 occurs in some but not
all cells.
Several studies in both females and males have correlated
the severity of intellectual disability with FMR1 activity and
FMRP levels (Dyer-Friedman et al. 2002; Loesch et al. 2004;
Reiss et al. 1995; Tassone et al. 1999). However, the variance
reported in cognitive outcomes for males is also substantially
influenced by the home environment, which is not the case for
females (Dyer-Friedman et al. 2002; Hessl et al. 2001).
Examination of the relationship between cognition and the
molecular pathology of FXS has been limited by the sensitiv-
ity and floor effects of cognitive testing methods in very low
functioning individuals. Only by developing new testing
methods and/or algorithms for interpreting results from cur-
rently available cognitive measures can the extent of the link
with FMRP levels be established. Table 1 provides details of
the studies reviewed here. A study in 2009 sought to minimize
the limitations associated with standard approaches to cogni-
tive testing in the FXS population, by normalizing scores on
the Wechsler Intelligence Scale for Children (WISC-III)
(Hessl et al. 2009). Normalized WISC-III scores were based
on raw score descriptive statistics from the publisher of the
WISC-III (Psychological Corporation, San Antonio, TX,
USA) and calculated using an age-dependent z-score trans-
formation. The new scores and usual standardized scores were
each correlated with the Vineland Adaptive Behavior Scales,
and FMRP levels and the results compared. This analysis
reported an enhanced correlation between cognition and re-
sidual FMRP expression for the new normalized scoring in
contrast to standardized scoring, providing a more accurate
assessment of the contribution of FMRP levels to cognitive
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skills in lower functioning individuals with FXS. Hessl et al.
(2001) were among the first to show that behavioral effects
correlated with FMRP expression levels. Correlations were
the strongest for internalizing problems in females, including
withdrawn and anxious/depressed behavior. In contrast, envi-
ronmental factors were shown to play a significant role in
behavioral problems for males (Hessl et al. 2001). In particu-
lar, non-pharmacological interventional therapy and the qual-
ity of the home environment were linked to fewer behavioral
and autistic symptoms (Hessl et al. 2001).
However, much of the variance in FXS phenotype remains
unexplained, and most available studies are compounded by
the methodology used to determine FMRP levels (Iwahashi
et al. 2009; Willemsen et al. 1995, 1997). In the past, FMRP
expression has been estimated indirectly using an immunocy-
tochemical approach to calculate the percentage of lympho-
cytes expressing any FMRP, without quantifying the amount
of FMRP expressed by the cell (Iwahashi et al. 2009;
Willemsen et al. 1995, 1997). More quantitative methods
capable of analyzing FMRP levels are required for improving
our understanding of the relationship between the molecular
pathology of FXS and the clinical phenotype. Furthermore,
recent observations report a cross-reaction between the anti-
FMRP monoclonal 7G1-1 and the RNA binding protein
Table 1 Description of studies linking cognition to FMRP levels
Study Population Cognitive measures FMRP levels/FMR1 activity Citation
Pedigree analysis of
children with FXS and
unaffected siblings
Aged 6–17 years WISC-III FMRP levels in peripheral
blood determined by
Immunocytochemistry
as % of FMRP-positive
lymphocytes
Dyer-Friedman et al. (2002);
Hessl et al. (2001)FXS: 80 M; 40 F
Mosaicism: 9 M; 5 F
Non-FXS siblings:
58 M; 62 F
Pedigree analysis of 144
families with individuals
affected by FXS
Aged 4–76 years WAIS-III; WISC-III;
WISC-R; WCST;
RCFT; BDS
FMRP levels in peripheral
blood determined by
Immunocytochemistry
as % of FMRP-positive
lymphocytes
Loesch et al. (2004)
Full mutationa: 87 M;
58 F
Premutationb:
32 M; 142 F
Non-FXS relatives:
114 M; 57 F
To specify and measure the
relative contributions of
genetics and epigenetic
characteristics to variance
in intellectual functioning
Aged 6–17 years WISC-R FMR1 activation ratio
determined from southern
blots of DNA extracted
from peripheral
lymphocytes
Reiss et al. (1995)
Full mutation: 29 F
Non-FXS: 50 F
Investigation of the relationship
between degree of FMRP
expression and deficits
associated with FXS
Aged 2–60 Leiter scale; WISC-R;
WISC-III;
WAIS-R; K-ABC;
S-B; BSID;
MDI; VABSc
FMRP levels in peripheral
blood determined by
Immunocytochemistry
as % of FMRP-positive
lymphocytes
Tassone et al. (1999)
Full mutation: 19 F
Completely methylated:
36 M
Partially methylated:
13 M
Repeat size mosaicism:
12 M
Examination of the sensitivity
of the WISC-III in FXS
Aged 6–17 years WISC-III FMRP levels in peripheral
blood determined by
Immunocytochemistry
as % of FMRP-positive
lymphocytes
Hessl et al. (2009)
Full mutation:
134 M; 83 F
Repeat size mosaicism:
44 M; 12 F
Methylation mosaicism:
13 M; 1 F
BDS Behavior Dyscontrol Scale, F females, M males, RCFT Rey Complex Figure Test, WAIS-III Weschler Adult Intelligence Scale—Third Edition,
WCST Wisconsin Card Sorting Test, WISC-III Weschler Intelligence Scale for Children—Third Edition, WISC-R WISC—Revised, K-ABC Kaufman
Assessment Battery for Children, S-B Stanford–Binet Intelligence test,MDI Mental Developmental Index, BSID Bayley Scales of Infant Development,
VABS Vineland Adaptive Behavior Scale
a Included individuals with repeat size mosaicism, unmethylated full mutation
b Included two individuals with 40–49 CGG repeats
c Used when standard IQ test could not be obtained
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Caprin 1 (El et al. 2012), suggesting that anti-FMRP antibod-
ies may not be as exclusive as previously thought. Other
FMR1 -related measures, such as DNA-methylation patterns
and the characterization of additional genetic variants at the
exome level, using next generation sequencing tools, may
provide other means of explaining phenotypic heterogeneity
in FXS.
Subgroups of FXS
Although FXS is usually associated with moderate to severe
intellectual disability, the syndrome can present as learning
difficulties in an individual with an IQ within the low normal
or borderline range (70–90); this is most often observed in
females. In one study, 50 % of females were placed in the
normal or borderline range (i.e., IQ>70) (de Vries et al. 1996).
Residual FMRP levels are in part related to the X-activation
ratio, potentially influencing the level of intellectual disability
in females (Dyer-Friedman et al. 2002; Loesch et al. 2004;
Reiss et al. 1995; Tassone et al. 1999). Clinical correlation of
FMRP expression levels in lymphocytes and brain cells may
be hampered by individual differences in the X-activation
ratios for brain and blood.
Higher-functioning (IQ>70) males with FXS also express
greater levels of FMRP than those individuals with more pro-
nounced deficits, due to mosaicism. Some of these mosaic males
have a proportion of cells containing a premutation expansion
(55–200 CGG repeats) and a proportion of cells with a full
mutation (size mosaicism). Other individuals have the full mu-
tation in both unmethylated and methylated forms (methylation
mosaicism) (Hagerman et al. 1994; Tassone et al. 1999).
Further evidence of clinical subgroups is provided by the
characterization of the Prader–Willi phenotype (PWP)
(McLennan et al. 2011). PWP occurs in <10 % of individuals
with FXS who present with hyperphagia, lack of satiation
after meals, and hypogonadism or delayed puberty, but test
negative for the 15q11–q13 deletion or uniparental maternal
disomy associated with Prader–Willi syndrome. Instead, a
study suggests that this subgroup has lowered expression of
a gene located on chromosome 15 in the 15q11–q13 region,
cytoplasmic FMR1 interacting protein 1 (CYFIP1 ) (Nowicki
et al. 2007). CYFIP1 interacts with FMRP and Rac1, linking
two processes which underlie synaptic remodeling—cytoskel-
etal reorganization and protein translation (Bardoni and
Mandel 2002; Schenck et al. 2003; Zarnescu et al. 2005).
FXS has been described in association with other etiologies
of intellectual disability, including autism, Down syndrome,
Klinefelter syndrome, Turner syndrome, and trisomy X
(Hagerman and Hagerman 2002). With the availability of
comparative genomic hybridization and whole exome analy-
ses, additional mutations may be uncovered in many more
patients with a primary diagnosis of FXS. The heterogeneity
in the FXS population and the varying treatment responses
observed in recent trials now require new paradigms to design
and implement future clinical trials for FXS.
Patient stratification for clinical trials
The appropriate selection of patients is crucial for any clinical
research. In the case of FXS, patients have typically been
selected based on a positive diagnostic test confirming the
expansion of >200 CGG repeats in the FMR1 promoter.
Treatments developed to target the underlying pathophysiol-
ogy of the syndrome may address symptoms directly associ-
ated with FMRP deficits, and their therapeutic efficacymay be
dependent largely on the extent of FMRP expression within
the patient population. Conversely, with molecular stratifica-
tion techniques, it may be possible to identify subpopulations
of patients with FXS who are more likely to respond to certain
treatments with specific molecular targets.
Molecular stratification of patients has been used in the clin-
ical development of the selective mGluR5 antagonist, AFQ056
(mavoglurant). In a proof-of-concept crossover-design study, 30
male patients with FXS, aged 18–35 years, were treated with
mavoglurant. A subgroup of patients with a completely methyl-
ated FMR1 promoter region were identified using a bisulfate-
sequencing based method, more sensitive than the widely used
Southern blot analysis. In a post hoc analysis, these individuals
showed significant improvements in Aberrant Behavior
Checklist—Community Edition (ABC-C) total score (−27.8 vs
placebo; p<0.001), despite no significant improvements in the
overall population (Jacquemont et al. 2011).
Following these results, efficacy studies have been initiated
in male and female adults and adolescents with FXS.
Molecular profiling is used to enrich the population with
completely methylated patients. Trials are designed with two
strata: patients who have completely methylated FMR1 pro-
moter regions and patients with a partially methylated pro-
moter, as assessed using a newly developed DNAmethylation
assay based on DNA-methylation-specific restriction en-
zymes and real-time PCR. These trials are ongoing and no
data are currently available.
The reasons for the significant response seen in the
completely methylated population and the variable response
among those in the partially methylated population in the
initial study are unknown. Possible factors include the rela-
tionship between methylation status and FMR1 mRNA and
FMRP expression (Jacquemont et al. 2011), resulting in a
range of severity and varied behavioral and cognitive dys-
function exhibited by the completely methylated groups, rel-
ative to the partially methylated group.
As we understand and identify the additional genetic and
environmental factors mediating phenotypic variability and
therapeutic response to treatments (for example, using
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techniques such as array-comparative genomic hybridization,
imaging genetics, whole genome, and exome sequencing), it
may be possible to identify reliable biomarkers and use these
to select patients most likely to benefit from specific treat-
ments. This should lead to better clinical trial designs and
lower attrition rates for FXS therapies.
Evaluating disease modification
Disease modification can be defined as a normalization or
partial normalization of the core mechanism underlying
FXS, which translates into a stabilization or improvement in
symptoms. Therefore, improvements across multiple symp-
tom domains in FXS (e.g., cognitive, behavioral, and neuro-
logical) could be considered as disease modifications. A key
challenge to assessing disease modification is identifying an
appropriate outcome measure, given the wide range of symp-
toms observed in this patient population. This is a critical
factor that needs to be considered when designing future
clinical trials evaluating disease modification.
Currently, it is unclear which measures are the most rele-
vant for these studies. A report by the National Institutes of
Health Working Outcome measures group concluded that
there is currently no single measure that can effectively eval-
uate treatment for FXS, based on a review of published data
(Berry-Kravis et al. 2013). They emphasized the need for
greater consistency in the selection of outcome measures in
clinical trials and the identification of a set of core measures
for FXS. The group favored a single-composite approach
grouping core features of FXS within each symptom domain.
Although this would be useful in studies of drugs which target
related symptoms, it might not detect improvements in a
single sub-domain. Other challenges facing a single-
composite approach include the variation in symptom presen-
tation associated with age and level of impairment, plus the
selection of features to be included in the measure. The ABC-
C, expressive language sampling, prepulse inhibition, and
neuroimaging were highlighted as promising measures in
need of further development. Also, the group recommended
testing outcome measures currently validated for other condi-
tions that share core symptoms with FXS for their feasibility
and validity in FXS.
As discussed in a recent review (Gross et al. 2012), any
outcome measure selected for a clinical trial in FXS must be
able to test a broad ability range, overcome problems of cooper-
ation and variable performance, be reproducible and quantifiable,
and show improvement in quality of life and function.
Recent trials of both mavoglurant (Jacquemont et al. 2011)
and STX209 (arbaclofen) (Berry-Kravis et al. 2012) have
looked at changes in the ABC-C and its subscales as clinical
endpoints. The ABC-C was developed to assess problem be-
haviors in children and adults with intellectual disability (Aman
et al. 1985) and has been effectively employed in trials for ASD
treatments. However, it was unknown if the ABC-C is sensitive
enough to detect disease modification in patients with FXS. A
version of the ABC-C has been developed with enhanced
specificity and sensitivity for FXS, ABC-C for FXS (Sansone
et al. 2012) (Fig. 1). In post hoc analyses of the mavoglurant
FXS trial, the responder subgroup (patients with a completely
methylated FMR1 promoter region) showed similar significant
improvements in both the ABC-C (−27.8 vs placebo; p <0.001)
(Jacquemont et al. 2011) and ABC-C for FXS (−25.61; p <
0.001) (Jaecklin et al., presented at the 13th International
Fragile X Conference, July 25–29, 2012, Miami, FL, USA).
Post hoc analyses of the arbaclofen phase II trial in children
and adults with FXS using the ABC-C for FXS scale reported
significant improvements in the Social Avoidance subscale
(−1.2 vs placebo; p =0.01), despite no significant improve-
ment in the other subscales of the ABC-C for FXS (Berry-
Kravis et al. 2012). Additional benefit was found in a sub-
group of patients with more severe social impairment at base-
line (ABC-C Lethargy/Social Withdrawal ≥8). In these pa-
tients, there was a significant improvement in the average
Social Avoidance subscale score (−2.2 vs placebo; p =0.04).
Other behavioral rating scales which have been used to
evaluate individuals with FXS and have shown sensitivity to
change are summarized in Table 2. In the mavoglurant study,
treatment benefits within the completely methylated popula-
tion were captured using the following scales: Visual
Analogue scale (VAS) ratings of parent-nominated behav-
iors, Clinical Global Impression—Severity (CGI-S) scale,
Clinical Global Impression—Improvement (CGI-I), CGI effi-
cacy index, Repetitive Behavior Scale—Revised, and Social
Responsiveness Scale—Adult Research Version, despite no
change in the primary endpoint (Jacquemont et al. 2011).
Similarly, VAS ratings showed improvements following
arbaclofen treatment in the entire per-protocol cohort, in the
absence of an improvement in the primary endpoint, the ABC-
C irritability subscale, or in other subscales of the ABC-C
(Berry-Kravis et al. 2012). Generally, the scales listed in
Table 2 are rarely used as primary outcome measures.
However, a phase II trial of minocycline in children and ado-
lescents with FXS used the CGI-I scale as the primary outcome
measure, reporting a significant overall improvement (2.49±
0.13 vs 2.97±0.13 in placebo; p =0.02) (Leigh et al. 2013).
Post hoc analyses of the VAS scores categorized according to
behavior observed significant changes in VAS ratings of parent-
nominated anxiety and mood-related behaviors (5.26±0.46 vs
4.05±0.46 in placebo; p =0.05).
The results of these studies suggest that rating scales can
detect therapeutic responses in patients with FXS, and appro-
priate selection of patients may avoid obscuring a treatment
response. They also highlight the importance of using
methods such as the ABC-C for FXS scale, which have been
validated in this patient population and are therefore more
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Irritability Lethargy Stereotypy Hyperactivity Inappropriate Speech Social Avoidance 
2. Injures self  12. Preoccupied, 
stares into space 
6. Meaningless, 
recurring 
movements 
1. Excessively 
active at home, 
school, work 
9. Talks 
excessively 
5. Seeks isolation 
4. Aggressive to 
others 
20. Fixed facial 
expression 
11. Stereotyped, 
repetitive behavior 
13. Impulsive 22. Repetitive 
speech 
16. Withdrawn, 
prefers solitary 
activities 
7. Boisterous 23. Only sits and 
watches others 
17. Bizarre in 
behavior 
15. Restless 33. Talks to self 
loudly 
30. Isolates 
him/herself 
8. Screams 
inappropriately 
25. Depressed mood 35. Repetitive 
hand, body, head 
movements 
28. No attention to 
instructions 
46. Repeats 
words/phrase over 
and over 
42. Prefers to be 
alone 
10. Temper 
tantrums 
32. Sits/stands in one 
position for a long 
time 
45. Waves/shakes 
extremities 
repeatedly 
31. Disrupts group 
activities 
14. Irritable and 
whiny 
37. Unresponsive to 
structured activities 
49. Rocks back 
and forth 
38. Does not stay 
in seat during 
lesson 
18. Disobedient 40. Is difficult to reach 
or contact 
27. Moves head 
back and forth  
39. Will not sit still 
for any length of 
time 
19. Yells 
inappropriately 
43. No word or 
gesture 
44. Easily 
distractible 
21. Disturbs others 51. Pays no attention 
when spoken to 
48. Constantly runs 
or jumps 
24. Uncooperative 53. Inactive, never 
moves spontaneously 
54. Excessively 
active 
29. Demands must 
be met immediately 
55. Responds 
negatively to affection 
34. Cries over minor 
annoyances 
56. Deliberately 
ignores directions 
36. Quick mood 
changes 
58. Shows few social 
reactions 
41. Cries/screams 
inappropriately 
3. Listless, sluggish, 
inactive  
47. Stamps 
feet/bangs 
objects/slams doors 
26. Resists physical 
contact  
50. Deliberately 
hurts him/herself 
52. Does physical 
violence to self 
57. Has outburst 
when doesn’t get 
way 
ABC-C scale factors not included in the ABC for FXS scale 
Irritability 
Lethargy 
Stereotypy 
Hyperactivity 
Inappropriate Speech 
Original categories  
from the ABC-C scale 
Fig. 1 ABC-C for FXS scale. Development of the ABC-C for FXS scale led to the addition of the new Social Avoidance subscale containing specific
factors from the ABC-C lethargy subscale
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sensitive to changes in specific FXS characteristics. Whether
or not the ABC-C for FXS scale can detect changes indicative
of disease modification is as yet unknown. Even though the
ABC-C may not capture improvements associated with clin-
ical treatment and despite the need to develop and use disease-
specific versions, the ABC-C remains the most accepted scale
for trials involving patients with developmental delay and
behavior issues.
The most appropriate measure for evaluating the extent of
disease modification will likely vary according to the age of
the patients. It is generally assumed that the younger the
patient at the time of treatment onset, the greater the therapeu-
tic benefit may be. This could potentially be assessed by
tracking improvements in developmental milestones (e.g.,
walking, toilet training, and language). Improvements in cog-
nitive function, using study designs investigating literacy and/
or numeracy skills after intensive non-pharmacological inter-
ventions (delivered with placebo-controlled trials of medica-
tions), may also provide an alternative approach to establish
disease modification. However, current cognitive outcome
measures (in particular standardized IQ tests) have not been
validated or standardized for populations with intellectual dis-
ability. These measures have inherent problems, such as floor
effects and learning effects (test retest effect), and alternative
approaches need to be validated within this patient population.
One approach, the Test of Attentional Performance for Children
(Testbatterie zur Aufmerksamkeitsprüfung für Kinder, KiTAP),
uses a computer-based approach to measure the core executive-
function deficits of attention and inhibition. In a recent pilot
study, the KiTAP showed that it could provide reliable and
clinically relevant scores in a population of individuals with
FXS over a wide range of age and function (Knox et al. 2012).
The appropriate timing of any intervention aimed at disease
modification is also important, as it is not yet clear if there are
age limits beyond which disease modification is no longer
possible. For example, preclinical data suggest that it is pos-
sible to rescue the FXS phenotype in adult Fmr1 -knockout
mice following chronic treatment with an mGluR5 antagonist
(Michalon et al. 2012), and no age-related effects were report-
ed in the recent trial evaluating arbaclofen in patients with
FXS aged 6–39 years (Berry-Kravis et al. 2012). Finally, any
study designed to quantify disease modification will need to
be multidimensional and longitudinal in order to effectively
track the rate of any changes that occur.
Multiple treatments targeting different mechanisms
involved in FXS
Mavoglurant was developed to therapeutically block
mGluR5, targeting the excessive glutamatergic signaling as-
sociated with a lack of FMRP (Levenga et al. 2011). Loss of
FMRP and the resultant mGluR5-dependent dysregulation of
synaptic plasticity are thought to contribute to the pathology
and symptomatology of FXS (Darnell et al. 2011; Jacquemont
et al. 2007; Levenga et al. 2010). This is referred to as the
mGluR theory of FXS, which proposes that inhibition of
group I mGluR signaling might be a potential therapeutic
target in FXS (Bear et al. 2004).
Following the results of studies that showed treatment with
mGluR5 antagonists, including mavoglurant, could rescue
several synaptic phenotypes in animal models (Choi et al.
2010; de Vrij et al. 2008; Levenga et al. 2011; McBride
et al. 2005; Tucker et al. 2006; Yan et al. 2005), it was
hypothesized that mavoglurant had the potential to treat the
underlying pathophysiology of FXS, thus differing from cur-
rent pharmacotherapy for FXS which is symptom-driven.
Other agents targeting specific molecular pathways are in
development for FXS (Table 3); these include RG7090
(RO4917523), another mGluR5 antagonist; STX209
(arbaclofen, R-baclofen), a γ-aminobutyric acid type B
(GABAB) receptor agonist (Berry-Kravis et al. 2012); and
minocycline, a matrix metalloproteinase-9 antagonist
(Bilousova et al. 2009; Leigh et al. 2013; Paribello et al.
2010; Utari et al. 2010). All of these agents aim to address
the underlying pathology of FXS by targeting specific molec-
ular pathways. However, there are currently no data linking
these specific pathways to particular symptoms of FXS.
Furthermore, there is a lack of biomarkers related to the
mechanism targeted by these new treatments (e.g., synaptic
plasticity rescued in animal models) preventing investigators
from evaluating how effective these agents are at targeting a
particular pathway.
What insights into ASD can be gained from studying
FXS?
ASD encompasses an etiology and clinically heterogeneous
population, which has posed challenges in the search to find
effective treatments. However, recent research shows promise
for the mapping of the multitude of aforementioned genetic
variants inASDonto shared pathways. Given the overwhelming
degree of locus heterogeneity, finding convergence in specific
molecular pathwayswill be required in order to perform targeted
treatment trials with sufficient sample size. Understanding the
molecular overlap between FXS and ASD, combined with
lessons learned from planning and running clinical trials for
FXS, may provide valuable insight into the most appropriate
study designs for investigating potential therapies in ASD.
We have previously highlighted the link between FMRP
and autism-candidate genes associated with synaptic plasticity
(Ascano et al. 2012; Darnell et al. 2011; Iossifov et al. 2012).
Lack of FMRP interferes with synaptic plasticity causing
disruption of various pathways, for example, up-regulation
of mGluR5 and mTOR signaling (Bear et al. 2004; Sharma
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et al. 2010) and down regulation of the GABA and dopamine
systems (D’Hulst and Kooy 2007; Wang et al. 2008).
The glutamate and GABA pathways have both been impli-
cated inASDby the use ofFmr1 KOmice as amodel system for
studying autistic behaviors (Rogers et al. 2013) and the increas-
ing evidence of altered expression of mGluR5, FMRP, and
GABA receptors in individuals with autism (Fatemi et al.
2010, 2011; Fatemi and Folsom 2011). Agents targeting these
two pathways in FXS (Table 3) may therefore be useful in ASD.
Research using models of FXS to elucidate converging molecu-
lar pathways behind autistic behaviors might identify novel
therapeutic targets for ASD. However, treatments targeting these
pathways could have different outcomes for individuals across
the ASD spectrum despite similarities in clinical presentation. To
illustrate, tuberous sclerosis complex (TSC) and FXS share
clinical characteristics (including ASD) and are caused by
haploinsufficiency of TSC1 and TSC2 associated with the regu-
lation of protein synthesis at the synapse (for review, see Orlova
and Crino 2010). In vivo data indicate that the synaptic dysfunc-
tion observed in mouse models of FXS and TSC falls at opposite
ends of the physiological spectrum (Auerbach et al. 2011; Bateup
et al. 2011) and can be rescued with agents that modulate
mGluR5 in opposite directions or by crossing the mouse strains
(Auerbach et al. 2011).
Given the wide range of symptoms observed in the ASD
patient population, clinical trials in ASD face similar problems
to trials in FXS in regard to patient selection and choice of
outcome measures. The development of biomarkers stratifica-
tion and endophenotyping methodologies in FXS trials could
be adapted for ASD trials. Likewise, new or modified mea-
sures (e.g., ABC-C for FXS) that can effectively track im-
provements in symptoms may also be transferable to studies
in ASD, but their feasibility across the ASD spectrum will
need to be tested. Because of the prevalence of autism in FXS
and shared neurophysiology with ASD, FXS can be viewed as
a model for autism.
Conclusions
Advances in understanding the neurobiology of “monogenic”
syndromes such as FXS have revealed heterogeneity at the
level of phenotype, manifestations of the causative mutation,
and drug response. Complex disorders such as ASD are
further complicated by increasing evidence for a heteroge-
neous etiology and mechanism of disease, unlike FXS which
is caused by a mutation within a single genetic locus, the
FMR1 gene. Current research is focused on identifying com-
mon therapeutic targets among patients with different molec-
ular etiologies. The development of novel treatments for spe-
cific molecular targets for these disorders has the potential to
rescue specific phenotypes and may result in what can be
classified as disease modification.
Developing biomarkers may aid patient stratification for
clinical trials and predict response to treatments. In addition
to patient stratification methods, future clinical trial designs
will also need to consider appropriate endpoints and length
and timing of interventions (Fig. 2). Ultimately, it may be
possible to stratify patients for genetic risk factors associated
with neurodevelopmental disorders such as FXS and ASD,
to enable early implementation of customized therapeutic
interventions that could normalize brain development and
optimize clinical outcomes.
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